1Half E, Broaddus R, Danenberg KD, et al. HER - 2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer, 2004, 108:540-548.
2Sekharam M, Zhao H, Sun M, et al. Insulin - like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt//3cl - x (L) pathway. Cancer Res, 2003, 63:7708-7716.
3Chun Y J, Park S, Yang SA, et al. Activation of Fas receptor modulates cytochrome P450 3A4 expression in human colon carcinoma cells. Toxicol Lett, 2003, 146:75-81.
4Ohana G, Bar Yehuda S, Arich A, et al. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. Br J Cancer, 2003, 89: 1552- 1558.
5FIainsworth JD, Sosrnan JA, Spigel DR, et al. Phase Ⅱ trial ofbevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). Proc Am Soc Clin Oncol, 2004, 22: 382s (abstr 4502).
6Motzer RJ, Rini BI, Michaelson MD, et al. SUO 11248, a novel tyrosine kinase inhibitor, shows antitumor activity in secondline therapy for patients with metastatic renal cell carcinoma:results of a phase 2 trial. Proc Am Soc Clin Oncol, 2004, 22 :382s (abstr 4500).
7Drach J, Kaufmarm H, Woehrer S, et al. Durable remissions after rituximab plus tha. lidomide for relapsed/refractory mantle cell lymphoma. Proc Am Soc Clin Oncol, 2004, 22: 578s (abstr 6583).
